GlassScriptPhysician profile
Omar Al Omari
NPI 1447863618
$4,586.72
in general payments reported to CMS, 2019-2025
12 companies · $4,211 in 2025
The $4,211 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.88 · 2022: $153 · 2023: $62.04 · 2024: $110 · 2025: $4,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,305 · Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,305.14 |
| Food and Beverage | $1,077.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,308.38 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medical Device Business Services, INC. | $1,108.58 | 2025 | Monarch |
| Astrazeneca Pharmaceuticals LP | $269.58 | 2021-2025 | Fasenra, Airsupra, Lokelma |
| Noah Medical Corporation | $150.00 | 2025 | Galaxy |
| Olympus Corporation of The Americas | $147.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.06 | 2025 | |
| Pfizer INC. | $125.62 | 2021-2022 | |
| Glaxosmithkline, LLC. | $121.84 | 2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $119.70 | 2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $51.37 | 2022 | |
| Amgen INC. | $23.06 | 2023 | Repatha |
| Merck Sharp & Dohme LLC | $15.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Al Omari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.